BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/20/2024 8:20:02 AM | Browse: 412 | Download: 805
Publication Name World Journal of Hepatology
Manuscript ID 93037
Country United States
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both
Manuscript Source Invited Manuscript
All Author List Rochelle Wong and Li-Yun Yuan
Funding Agency and Grant Number
Corresponding Author Rochelle Wong, MD, Doctor, Doctor, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, 1510 San Pablo St. HC1 - Suite 200, Los Angeles, CA 90033, United States. rochellewong15@gmail.com
Key Words Sarcopenia; Steatotic liver disease; Metabolic dysfunction; Insulin resistance; Liver-muscle axis
Core Tip Sarcopenia and metabolic dysfunction associated steatotic liver disease (MASLD) share a bidirectional relationship along the liver-muscle axis. With similar pathophysiology and shared risk factors, MASLD is a risk factor for sarcopenia, and vice versa. Early identification and adequate diagnosis are important. However, lack of consensus definition made it difficult to research outcomes. With the recently updated consensus definition for MASLD, researchers may now better identify proper cohorts for study. Consensus on gold standard techniques and muscle mass cutoffs to define sarcopenia are still needed. Future research may identify potential therapeutic targets along the shared liver-muscle axis that would improve outcomes for both sarcopenia and MASLD.
Publish Date 2024-06-20 03:42
Citation

Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both. World J Hepatol 2024; 16(6): 871-877

URL https://www.wjgnet.com/1948-5182/full/v16/i6/871.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i6.871
Full Article (PDF) WJH-16-871-with-cover.pdf